          |
 |
< Previous | 2019 Agenda and Abstracts | Next >
2019
OMIG Abstract Purpose: We aim to describe the epidemiology of ocular infections and associated antibiotic resistance for a public tertiary care hospital in New York City (NYC). Methods: We retrospectively reviewed 558 patients with ocular cultures during a period of 9 years (2009-2017). We reviewed microbial growth, antibiotic sensitivities, antibiotic treatment, primary diagnosis and patient risk factors for infection. Results: Across all cultures with growth 185/558 (33%), the most common microbes were Staphylococcus aureus 43/185 (23%), coagulase negative Staphylococcus (CoNS) 42/185 (23%), Pseudomonas aeruginosa 30/185 (16%), Streptococcus viridans group 20/185 (11%), Serratia marcescens 15/185 (8%), Haemophilus influenzae 13/185 (7%), and Streptococcus pneumoniae 9/185 (5%). For cases of keratitis 61/185 (33%), the most common microbes were P. aeruginosa 23/61 (37%), S. marcescens 10/61 (16%), S. viridans group 7/61 (11%), and CoNS 7/61 (11%). For cases of conjunctivitis 34/185 (18%), most common microbes were S. aureus 12/34 (35%), CoNS 11/34 (32%), S. viridans group 7/34 (21%), and H. influenzae 4/34 (12%). 134 of 558 (24%) cultures were positive for microbial growth with additional analysis of antibiotic sensitivities. MRSA (n = 11/17) exhibited multidrug resistance more than four times as often as MSSA (n = 4/25) (65% vs. 16%). Diabetic patients (p = 0.0109) were more often associated MRSA (4/17) than MSSA (0/25). Resistant P. aeruginosa (33.3%, n = 10/30) was more often from a corneal source (80%, p=0.0089) than any other source. Fluoroquinolone resistance was exhibited in 11 isolates (8% of 134).
Conclusion: Microbial and antimicrobial profiles of ocular infection of a public tertiary care hospital in NYC is distinct from other geographies studied in literature. In this study, the distinct diversity and frequency of pathogens by ocular source can inform empiric therapy selection for patients with conjunctivitis, keratitis, and endophthalmitis.
Disclosure: N
<Previous | 2019 Agenda and Abstracts | Next >
|
|
